Global ADME-Toxicology Testing Markets 2016-2024: Strategic Business Report 2018 -- Need for Better Models: A Major Factor Driving Innovation in the Market

DUBLIN, July 12, 2018 /PRNewswire/ --

The "ADME-Toxicology Testing - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.

The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2016 through 2024. Also, a five-year historic analysis is provided for these markets.

This report analyzes the worldwide markets in US$ by the following Segments:

• Toxicology Testing (In-Vivo, In-Vitro)
• ADME Testing
  

The report profiles 69 companies including many key and niche players such as:

• ACEA Biosciences, Inc. (USA)
• ADMEcell, Inc. (USA)
• Agilent Technologies, Inc. (USA)
• Albany Molecular Research, Inc. (USA)
• Beckman Coulter, Inc. (USA)
• BioreclamationIVT, LLC (USA)
• Cerep SA (France)
• CompuDrug International, Inc. (USA)
• Cyprotex PLC. (UK)
• CeeTox, Inc. (USA)
• Dassault Systmes Biovia Corp. (USA)
• Eurofins ADME BIOANALYSES SAS (France)
• Galapagos NV (Belgium)
• Molecular Discovery Ltd. (UK)
• MultiCASE, Inc. (USA)
• Optivia Biotechnology (USA)
• PerkinElmer, Inc. (USA)
• Pharmaron, Inc. (USA)
• Promega Corporation (USA)
• Qualyst, Inc. (USA)
• Simulations Plus, Inc. (USA)
• Taconic Biosciences, Inc. (USA)
• Takara Bio Europe AB (Sweden)
• Tecan Group Ltd. (Switzerland)
• Thermo Fisher Scientific, Inc. (USA)

Key Topics Covered

1. OUTLOOK
ADME-Tox Testing Gains Traction
A Peek into the Impact of ADME-Tox Screening on New Drug Discovery
Current and Future Analysis
US and Europe Dominate, Asia-Pacific Lends Growth Momentum
Growth Momentum Shifts Away from In Vivo Technologies; In Vitro Technologies to Lead the Charge

2. INDUSTRY OVERVIEW
Pharma Industry Renews Focus on Cost Optimization
China and India: Hot Spots for R&D Investment
ADME-Tox Assays
An Overview
Introduction of Early In Vitro ADMET Studies
Growing Prominence of Cell-based Assays in Drug Discovery and ADME Analysis
Major Types of Cell-Based HTS Assays for Drug Screening
CROs Expand Presence
Drug Discovery Outsourcing and Type of Services Outsourced
Changing Face of Drug Discovery Outsourcing Activity
M&A
Order of the Day

3. MARKET DYNAMICS
Current State of ADME-Tox Testing
Need for Better Models: A Major Factor Driving Innovation in the Market
Focus Shifts to Innovative Approaches
In Silico and In Vitro- the Way to Go
In Vitro Testing Systems and Its Relevance in Drug Development
In Silico ADME-Tox Growing at a Fast Clip
3-D Tissue Bioassays to Enhance In Vitro Toxicity Testing
Increasing Use of Cell-Based Assays over Other Methods in Toxicity Testing
Rising Number of Drug Targets Surge Demand for Cell-Based Assays
Growing Focus on the Development of Reproducible and Robust Cell-based Assays
Functional Assays: An Effective Way of Predicting Specific Toxic Effects
GPCR Targets to Drive Growth in Functional Cell Assay Market
New Alternatives for Early-Stage Toxicology Testing
Stem Cells Exude Great Potential in Drug Toxicity Testing
Primary Hepatocytes Become Standard Tool for Evaluation in Hepatic Metabolism
Improved Cryopreservation Technologies Help Expand Use of Hepatocytes
Cardiotoxicity Testing Gains Prominence
Cell Imaging-Gaining Popularity
In Vivo Imaging Persists in ADME-Tox Testing
Computational Models on Rise
Adoption of Data Management Systems
Drug Transporter Analysis Becoming Part of ADME Assessment
Slow Metabolism of Novel Drugs Call for More Human Models in Screening
Further Advances Required for More Understanding of Biotransformation
Introduction of Third Dimension in Cell Culturing Drives Need for New Instrumentation
Regulatory Bodies Focus on Transporter Mediated DDIs

4. DRUG DISCOVERY & DEVELOPMENT
Overview
Drug Discovery and Development
Target identification
Target Validation
Lead Identification
Lead Optimization
Pre-Clinical Testing
Clinical Trials
Drug Discovery Technologies
Innovation in Screening Guarantees Success for Drug Discovery Programs

5. PRODUCT OVERVIEW

6. PRODUCT INNOVATIONS/INTRODUCTIONS
Corning Adds Two New Products to ADME/Tox Lineup
Sovicell and 3B Pharmaceuticals Launch EScalate Assay Service
Lonza Launches Human and Animal Hepatocytes for Adme-Tox Testing
Cyprotex Launches Eight New Transporter Assays
Simulations Plus Rolls Out Version 8.0 of ADMET Predictor Software
Simulations Plus Launches Version 7.2 of ADMET Predictor Software
BioReliance Unveils Select In Vitro ADME and Toxicology Testing Services
Cyprotex Releases SenCeeTox Technology with Enhanced Capabilities
Cyprotex Expands In-House Drug Transporter Services
Cyprotex Launches KeratinoSens Service
Simulations Plus Introduces ADMET Predictor Version 7.1
Lena Biosciences Launches SeedEZ 3D Cell Culture Products
Sigma Life Science to Introduce Genetically-Modified HepaRG Human Liver Cell Line

7. RECENT INDUSTRY ACTIVITY
Simulations Plus to Take Over DILIsym Services
Simulations Plus and Electrolab India Sign Distribution Deal
Simulations Plus Inks Distribution Deal with Quantum Bio Solutions for Korean Market
Cyprotex Moves to New Location in the UK
Pharmaron Takes Over Xceleron
Evotec Acquires Cyprotex
Endonovo Expands Cytotronics Platform for Toxicology Testing
Takara Bio Acquires Cellectis AB
WuXi PharmaTech Acquires XenoBiotic Laboratories
Merck KGaA to Take Over Sigma-Aldrich
Dassault Systmes Acquires Accelrys
Organovo Collaborates with J&J for 3D Bioprinting Drug Discovery Research
Taconic and IVAL Enter into Agreement
Charles River to Acquire Galapagos' Argenta and BioFocus Service Divisions
Simulations Plus Signs 5-Year RCA with the US FDA
Simulation Plus Inks Distributor Agreement with RILD
Harlan CRS Enters into Strategic Alliance with Bertin Pharma
Pharmaron Receives GLP Certification from the CFDA for GLP Toxicology Facilities
Cyprotex Acquires CeeTox
Taconic Announces Name Change
Rosa & Co. Acquires Entelos Holdings' Consulting Service Business
Thermo Fisher Scientific Acquires Life Technologies

8. FOCUS ON SELECT PLAYERS
ACEA Biosciences, Inc. (USA)
ADMEcell, Inc. (USA)
Agilent Technologies, Inc. (USA)
Albany Molecular Research, Inc. (USA)
Beckman Coulter, Inc. (USA)
BioreclamationIVT, LLC (USA)
Cerep SA (France)
CompuDrug International, Inc. (USA)
Cyprotex PLC. (UK)
CeeTox, Inc. (USA)
Dassault Systmes Biovia Corp. (USA)
Eurofins ADME BIOANALYSES SAS (France)
Galapagos NV (Belgium)
Molecular Discovery Ltd. (UK)
MultiCASE, Inc. (USA)
Optivia Biotechnology (USA)
PerkinElmer, Inc. (USA)
Pharmaron, Inc. (USA)
Promega Corporation (USA)
Qualyst, Inc. (USA)
Simulations Plus, Inc. (USA)
Taconic Biosciences, Inc. (USA)
Takara Bio Europe AB (Sweden)
Tecan Group Ltd. (Switzerland)
Thermo Fisher Scientific, Inc. (USA)

9. GLOBAL MARKET PERSPECTIVE

Total Companies Profiled: 69 (including Divisions/Subsidiaries 77)

• The United States (46)
• Canada (2)
• Japan (1)
• Europe (24)
• France (4)
• Germany (3)
• The United Kingdom (6)
• Spain (1)
• Rest of Europe (10)
• Asia-Pacific (Excluding Japan) (4)

For more information about this report visit https://www.researchandmarkets.com/research/mx5pgv/global?w=5

Did you know that we also offer Custom Research? Visit our Custom Research page to learn more and schedule a meeting with our Custom Research Manager.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

Related Links

http://www.researchandmarkets.com